PDCD1LG2 and breast carcinoma: Furthermore, research has identified an SE in breast cancer that elevates the levels of programmed death‐ligand 1 (PD‐L1) and programmed death‐ligand 2 (PD‐L2), thereby helping tumours evade the immune system [130].